Daratumumab-EPOCH for transformed anaplastic multiple myeloma.
作者信息
Stormorken Espen, Dahm Anders Erik Astrup
机构信息
Department of Haematology, Akershus University Hospital, Lørenskog, Norway.
Department of Haematology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
出版信息
Hematol Transfus Cell Ther. 2025 Sep 6;47(4):103977. doi: 10.1016/j.htct.2025.103977.
Abstract
摘要
相似文献
1
Daratumumab-EPOCH for transformed anaplastic multiple myeloma.达雷妥尤单抗联合EPOCH方案治疗转化型间变性多发性骨髓瘤。
Hematol Transfus Cell Ther. 2025 Sep 6;47(4):103977. doi: 10.1016/j.htct.2025.103977.
2
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.达雷妥尤单抗或高危冒烟型多发性骨髓瘤的主动监测
N Engl J Med. 2025 May 8;392(18):1777-1788. doi: 10.1056/NEJMoa2409029. Epub 2024 Dec 9.
3
Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis.达雷妥尤单抗联合标准治疗方案用于初诊多发性骨髓瘤患者：一项网状 Meta 分析。
Eur J Haematol. 2019 Dec;103(6):542-551. doi: 10.1111/ejh.13317. Epub 2019 Oct 1.
4
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.达雷妥尤单抗-来那度胺和达雷妥尤单抗-泊马度胺在复发性来那度胺暴露或难治性多发性骨髓瘤中的应用。
Anticancer Drugs. 2024 Jan 1;35(1):63-69. doi: 10.1097/CAD.0000000000001520. Epub 2023 Apr 6.
5
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗，随后进行达雷妥尤单抗维持或观察治疗，适用于适合移植的新诊断多发性骨髓瘤：CASSIOPEIA 随机对照 3 期试验的长期随访。
Lancet Oncol. 2024 Aug;25(8):1003-1014. doi: 10.1016/S1470-2045(24)00282-1. Epub 2024 Jun 15.
6
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.复发或难治性多发性骨髓瘤患者中，贝兰他单抗马福多汀、硼替佐米与地塞米松联合用药对比达雷妥尤单抗、硼替佐米与地塞米松联合用药的患者报告结局（DREAMM-7）：一项3期、开放标签、随机对照试验的结果
Lancet Haematol. 2025 Jul 15. doi: 10.1016/S2352-3026(25)00163-2.
7
Daratumumab for the treatment of multiple myeloma.达雷妥尤单抗用于治疗多发性骨髓瘤。
Drugs Today (Barc). 2021 Oct;57(10):591-605. doi: 10.1358/dot.2021.57.10.3313853.
8
Meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma.达雷妥尤单抗治疗多发性骨髓瘤疗效与安全性的荟萃分析。
World J Clin Cases. 2023 Oct 16;11(29):7091-7100. doi: 10.12998/wjcc.v11.i29.7091.
9
Exploring the Relationship Between Daratumumab Treatment and Stem Cell Collection in Newly Diagnosed Multiple Myeloma (NDMM) Patients Undergoing Transplantation: Insights From a Single-Center Investigation.探索达雷妥尤单抗治疗与接受移植的新诊断多发性骨髓瘤（NDMM）患者干细胞采集之间的关系：来自单中心调查的见解
Indian J Hematol Blood Transfus. 2025 Oct;41(4):942-946. doi: 10.1007/s12288-024-01914-8. Epub 2024 Nov 14.
10
Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.新型单克隆抗体治疗复发/难治性多发性骨髓瘤疗效与安全性的系统评价和荟萃分析
Oncotarget. 2017 May 16;8(20):34001-34017. doi: 10.18632/oncotarget.16987.
本文引用的文献
1
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.塔奎单抗，一种用于多发性骨髓瘤的靶向 GPRC5D 的 T 细胞双特异性抗体。
N Engl J Med. 2022 Dec 15;387(24):2232-2244. doi: 10.1056/NEJMoa2204591. Epub 2022 Dec 10.
2
Anaplastic multiple myeloma with MYC rearrangement.伴有MYC重排的间变性多发性骨髓瘤
Leuk Res Rep. 2021 Dec 27;17:100288. doi: 10.1016/j.lrr.2021.100288. eCollection 2022.
3
Anaplastic Multiple Myeloma with Multiple Genetic Anomalies.间变大细胞多发性骨髓瘤伴多种遗传学异常。
J Coll Physicians Surg Pak. 2022 Jan;32(1):132-133. doi: 10.29271/jcpsp.2022.01.132.
4
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.多发性骨髓瘤：欧洲血液学协会-欧洲肿瘤内科学会诊断、治疗及随访临床实践指南
Ann Oncol. 2021 Mar;32(3):309-322. doi: 10.1016/j.annonc.2020.11.014. Epub 2021 Feb 3.
5
Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy.来那度胺、环磷酰胺和地塞米松治疗间变性多发性骨髓瘤取得成功结果。
Ann Hematol. 2021 Dec;100(12):3039-3040. doi: 10.1007/s00277-020-04244-7. Epub 2020 Sep 2.
6
Clinical and histopathological analyses of anaplastic myeloma.间变性骨髓瘤的临床与组织病理学分析
Chin Med J (Engl). 2020 Jul 5;133(13):1614-1616. doi: 10.1097/CM9.0000000000000902.
7
Anaplastic multiple myeloma: possible limitations of conventional chemotherapy for long-term remission.间变性多发性骨髓瘤：传统化疗实现长期缓解的可能局限性。
J Clin Exp Hematop. 2018;58(1):39-42. doi: 10.3960/jslrt.17035.
8
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.EPOCH化疗：复发难治性非霍奇金淋巴瘤的毒性和疗效
J Clin Oncol. 1993 Aug;11(8):1573-82. doi: 10.1200/JCO.1993.11.8.1573.
9
Pomp combination chemotherapy of adult acute leukemia.
Cancer. 1973 Jul;32(1):69-75. doi: 10.1002/1097-0142(197307)32:1<69::aid-cncr2820320109>3.0.co;2-0.
10
Aggressive phase multiple myeloma: a terminal anaplastic transformation resembling high-grade lymphoma.
Cancer Invest. 1990;8(3-4):417-24. doi: 10.3109/07357909009012059.
Zotero 插件